Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA

Axogen, Inc.

2024-Q3 EPS reported -$0.24 revenue$137,933,000

Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.
Net loss $1.9M ($0.04/shr) vs $4.1M ($0.10/shr); adjusted net income $3.1M ($0.07/shr).
Adjusted EBITDA $6.5M vs $2.4M in Q3 2023; cash $30.5M at quarter end.
FDA accepted BLA for Avance Nerve Graft under standard review; PDUFA date Sept 5, 2025; no advisory committee planned.
2024 revenue guidance reaffirmed $182M-$186M; expects high end of gross margin range and cumulative net cash flow positive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.